• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

    4/8/25 11:22:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QGEN alert in real time by email

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025.

    Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

    Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.

    Three options for joining the conference call

    Register for call back connection - Click here: Connect me

    Service is available 15 minutes before the call starts

    Dial-in by phone

    U.S.: +1 646 828 8193

    UK: +44 (0)330 165 3655

    GER: +49 (0)69 6610 2480

    Conference ID: 5803222

    To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

    Access the audio webcast - Click here: Access Webcast

    A conference call replay will be available by using the following link: https://event.webcasts.com/starthere.jsp?ei=1684140&tp_key=ac10da14a0

    Contact: [email protected]

    About QIAGEN

    QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

    source: QIAGEN N.V.

    category: Financial

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250408330643/en/

    John Gilardi

    Vice President Head of Corporate Communications

    +49 2103 29 11711

    +49 152 018 11711

    +1 240 686 2222

    Email: [email protected]



    Domenica Martorana

    Associate Director Investor Relations

    +49 2103 29 11244

    +49 152 018 11244

    Email: [email protected]

    Get the next $QGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QGEN

    DatePrice TargetRatingAnalyst
    4/4/2025Buy → Neutral
    Redburn Atlantic
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    6/27/2024$50.00Peer Perform → Outperform
    Wolfe Research
    12/19/2023$44.00Equal Weight
    Wells Fargo
    12/13/2023Peer Perform
    Wolfe Research
    More analyst ratings